## Background and objectives: Most patients with colorectal liver metastases are not eligible for resection because they have multiple lesions or because of anatomical constraints. we report the use of cryotherapy to destroy residual metastases following liver resection in patients with disease too
Cryotherapy for neuroendocrine liver metastases
โ Scribed by Joachim K. Seifert; Paul J. Cozzi; David L. Morris
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 233 KB
- Volume
- 14
- Category
- Article
- ISSN
- 8756-0437
No coin nor oath required. For personal study only.
โฆ Synopsis
While the prognosis for patients with untreated liver metastases from neuroendocrine primaries is rather good, they often suffer disabling symptoms due to syndromes of hormonal excess. Thirteen patients with metastatic neuroendocrine tumours were treated by hepatic cryotherapy; seven patients were symptomatic and five of these had elevated levels of hormonal tumour markers. Twelve patients are alive and mostly asymptomatic with a median follow up of 13.5 months; one patient died after 45 months of bronchopneumonia without evidence of tumour recurrence. All patients with elevated preoperative tumour markers have had a significant fall in markers postoperatively. Two patients were returned to the operating theatre for coagulopathy-associated bleeding: one patient each developed acute renal failure and pulmonary embolism, but there was no mortality. This study shows that hepatic cryotherapy offers a useful treatment option for this group of patients, alleviates symptoms and may have an impact on survival.
๐ SIMILAR VOLUMES
One hundred fifty-eight procedures were performed on 136 patients with unresectable hepatic metastases using hepatic cryotherapy to ablate the tumors. The median age was 62 years. Patients included 90 males and 46 females. Fifty-eight patients had synchronous metastases, 55 had bilobar lesions, and
the in situ freezing of tumor, i.e., cryotherapy, was performed with liquid nitrogen (-196ยฐC) on 235 patients with primary liver cancer (PLC). There were no operative mortalities or severe complications. The 5-year survival was 39.8% for the 235 PLC patients, and 55.4% for the 80 patients with small
## Background and objectives: After curative resection of hepatic colorectal metastases, 10-20% of patients experience a resectable hepatic recurrence. we wanted to assess the expected risk-to-benefit ratio in comparison to first hepatectomy and to determine the prognostic factors associated with s